| Item 1. | Security and Issuer |
| (a) | Title of Class of Securities:
Common Stock, par value $0.001 per share |
| (b) | Name of Issuer:
Kezar Life Sciences, Inc. |
| (c) | Address of Issuer's Principal Executive Offices:
4000 Shoreline Court, Suite 300, South San Francisco,
CALIFORNIA
, 94080. |
Item 1 Comment:
This Schedule 13D/A (this "Statement") amends the Schedule 13D (the "Original Schedule 13D") filed on October 8, 2024. Items 2, 4, 5 and 7 of the Statement are hereby amended and supplemented to the extent hereinafter expressly set forth. Except as amended hereby, the original disclosure set forth in the Statement shall remain unchanged. All capitalized terms used and not expressly defined herein have the respective meanings ascribed to such terms in the Original Schedule 13D. |
| Item 2. | Identity and Background |
|
| (a) | The information previously provided in response to Item 2 is hereby amended and restated by replacing the text thereof in its entirety with the following:
This Statement is filed by TCM, a Delaware limited liability company that is the general partner of Tang Capital Partners, LP ("TCP") and TCPI; Kevin Tang, a United States citizen; TCP, a Delaware limited partnership engaged in capital management; TCPI, a Delaware limited partnership engaged in capital management; TCP III, a Nevada corporation that is indirectly wholly owned by TCP; Tang Capital Partners IV, Inc., a Nevada corporation that is indirectly wholly owned by TCP ("TCP IV"); and Concentra Biosciences, LLC, a Delaware limited liability company controlled by TCP ("Concentra" and, collectively with TCM, Kevin Tang, TCP, TCPI, TCP III and TCP IV, the "Reporting Persons"). |
| (b) | The address of TCM, Kevin Tang, TCP, TCPI and Concentra is 4747 Executive Drive, Suite 210, San Diego, CA 92121. The address of TCP III and TCP IV is 400 S. 4th Street, 3rd Floor, Las Vegas, NV 89101. |
| (c) | Kevin Tang is the manager of TCM. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV. Kevin Tang is the Chief Executive Officer of Concentra. |
| (d) | During the past five years, none of the Reporting Persons have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). |
| (e) | During the past five years, none of the Reporting Persons have been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. |
| (f) | See Item 2(a) above. |
| Item 4. | Purpose of Transaction |
| | Item 4 of the Original Schedule 13D is hereby amended to add the following:
Tender and Support Agreement:
On March 30, 2026, in connection with the execution of the Agreement and Plan of Merger, dated as of March 30, 2026 by and among the Issuer, Aurinia Pharma U.S., Inc., Aurinia Merger Sub, Inc. and Aurinia Pharmaceuticals, Inc. (the "Merger Agreement," attached as Exhibit 3), the Reporting Persons entered into a tender and support agreement (attached as Exhibit 4) pursuant to which the Reporting Persons agreed, among other things, (i) to tender all of the Shares held by the Reporting Persons (the "Subject Shares"), subject to certain exceptions (including the valid termination of the Merger Agreement), and (ii) to certain other restrictions on its ability to take actions with respect to the Issuer and the Subject Shares.
Rescission of Acquisition Proposal:
Concentra has also rescinded the acquisition proposal to acquire 100% of the equity of the Issuer that was originally sent on October 8, 2024. |
| Item 5. | Interest in Securities of the Issuer |
| (a) | The information previously provided in response to Item 5 is hereby amended and restated by replacing the text thereof in its entirety with the following:
The information set forth in the cover pages of this Schedule 13D is hereby incorporated by reference into this Item 5. As of the date hereof the Reporting Persons beneficially own an aggregate of 664,314 shares of the Issuer's Common Stock, representing 9.0% of the outstanding shares. |
| (b) | See item 5(a) above. |
| (c) | There have been no transactions in the Issuer's Common Stock during the past 60 days by the Reporting Persons. |
| (d) | No person other than a Reporting Person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Common Stock beneficially owned by the Reporting Persons. |
| (e) | Not applicable |
| Item 7. | Material to be Filed as Exhibits. |
| | Exhibit 1: Joint Filing Agreement by and among the Reporting Persons (filed as Exhibit 1 of the 13D filed on October 8, 2024 by the Reporting Persons with respect to the Common Stock of the Issuer).
Exhibit 2: Schedule A: Transactions during the past 60 days (filed as Exhibit 2 of the 13D filed on October 8, 2024 by the Reporting Persons with respect to the Common Stock of the Issuer).
Exhibit 3: Agreement and Plan of Merger, dated as of March 30, 2026, by and among the Issuer, Aurinia Pharma U.S., Inc., Aurinia Merger Sub, Inc. and Aurinia Pharmaceuticals, Inc. (filed as Exhibit 2.1 of the Issuer's Current Report filed on Form 8-K on March 30, 2026).
Exhibit 4: Form of Tender and Support Agreement, dated as of March 30, 2026, by and among Aurinia Pharma U.S., Inc., Aurinia Merger Sub, Inc., the Issuer and the stockholders party thereto (filed as Exhibit 10.1 of the Issuer's Current Report filed on Form 8-K on March 30, 2026). |
